Pay in 4 interest-free payments of $6.37 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Im not so sure I want to be on another
Compared to non-GLP-1RA anti-obesity medications, semaglutide was associated with a significantly lower risk of recurrent AUD diagnosis (0.37% vs 0.73%
Cross-reactivity with other GLP-1 receptor agonists is uncertain and would require specialist assessment Insulin therapy : various regimens available, from once-daily basal insulin to multiple daily injections, depending on individual needs According to NICE guidance (NG28), treatment intensification should be individualised, considering: HbA1c targets and current glycaemic control Cardiovascular or renal comorbidities (where SGLT2 inhibitors may be preferred) Risk of hypoglycaemia Impact on body weight Patient preferences and ability to adhere to treatment Lifestyle modifications remain fundamental to diabetes management regardless of medication: Structured education programmes (such as DESMOND) Dietary modifications with support from a dietitian Regular physical activity Weight management where appropriate Smoking cessation and alcohol moderation Your diabetes care team, which may include your GP, practice nurse, diabetes specialist nurse, and consultant endocrinologist, will review your treatment plan regularly and adjust medications as needed to achieve optimal glycaemic control whilst minimising side effects and risks
This is the gold standard in clinical research
Pharmacy and Therapeutics, 273-276
